Evidence map›Paper›PMID 33528536›Full record

ArticleJAMA2021

Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy.

Andrés Moreno-De-Luca, Francisca Millan, Denis R Pesacreta, Houda Z Elloumi, Matthew T Oetjens, Claire Teigen, Karen E Wain, Julie Scuffins, Scott M Myers, Rebecca I Torene and 6 more

Open access · greenAbstract read
In one paragraph

Article in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Shared and distinct phenotypic profiles among neurodevelopmental disorder genes.medRxiv : the preprint server for health sciences · 2026
    Article
  9. A Phenotypic Paradigm for Cerebral Palsy Genetics.medRxiv : the preprint server for health sciences · 2026
    Article
  10. Frontiers in neurology · 2026
    Article
  11. Article
  12. Article
  13. Genetic testing in cerebral palsy with clinical and neuroimaging variables.Developmental medicine and child neurology · 2025
    Article
  14. Article
  15. Insights into the genetic landscape of cerebral palsy.Clinical and translational medicine · 2025
    Article
  16. CTNNB1 syndrome mouse models.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  17. Article
  18. Article
  19. Monogenic disorders associated with motor speech phenotypes in children and adolescents undergoing clinical exome sequencing.Genetics in medicine : official journal of the American College of Medical Genetics · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Andrés Moreno-De-LucaAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Francisca MillanGeneDx, Gaithersburg, Maryland.
Denis R PesacretaAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Houda Z ElloumiGeneDx, Gaithersburg, Maryland.
Matthew T OetjensAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Claire TeigenGeneDx, Gaithersburg, Maryland.
Karen E WainAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Julie ScuffinsGeneDx, Gaithersburg, Maryland.
Scott M MyersAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Rebecca I ToreneGeneDx, Gaithersburg, Maryland.
Vladimir G GainullinGeneDx, Gaithersburg, Maryland.
Kevin ArvaiGeneDx, Gaithersburg, Maryland.
H Lester KirchnerDepartment of Population Health Sciences, Geisinger, Danville, Pennsylvania.
David H LedbetterAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Kyle RettererGeneDx, Gaithersburg, Maryland.
Christa L MartinAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Autism & Developmental Medicine Institute · USGeisinger Health System · USGeisinger Neuroscience Institute · US

Funding

GENE DOSAGE IMBALANCE IN NEURODEVELOPMENTAL DISORDERSR01MH074090 · NIMH · GEISINGER CLINIC · PI David H. Ledbetter, CHRISTA LESE MARTIN · 2005 to 2026
$13.5M
Gender differences in quantitative measures of autonomic function and clinical features of the autism phenotypeR01MH107431 · NIMH · GEISINGER CLINIC · PI MARTIN, CHRISTA LESE · 2015 to 2019
$3.4M
NIMH NIH HHS R01 MH074090NIMH NIH HHS R01 MH107431
6 · The paper itself

Abstract

Importance: Cerebral palsy is a common neurodevelopmental disorder affecting movement and posture that often co-occurs with other neurodevelopmental disorders. Individual cases of cerebral palsy are often attributed to birth asphyxia; however, recent studies indicate that asphyxia accounts for less than 10% of cerebral palsy cases. Objective: To determine the molecular diagnostic yield of exome sequencing (prevalence of pathogenic and likely pathogenic variants) in individuals with cerebral palsy. Design, Setting, and Participants: A retrospective cohort study of patients with cerebral palsy that included a clinical laboratory referral cohort with data accrued between 2012 and 2018 and a health care-based cohort with data accrued between 2007 and 2017. Exposures: Exome sequencing with copy number variant detection. Main Outcomes and Measures: The primary outcome was the molecular diagnostic yield of exome sequencing. Results: Among 1345 patients from the clinical laboratory referral cohort, the median age was 8.8 years (interquartile range, 4.4-14.7 years; range, 0.1-66 years) and 601 (45%) were female. Among 181 patients in the health care-based cohort, the median age was 41.9 years (interquartile range, 28.0-59.6 years; range, 4.8-89 years) and 96 (53%) were female. The molecular diagnostic yield of exome sequencing was 32.7% (95% CI, 30.2%-35.2%) in the clinical laboratory referral cohort and 10.5% (95% CI, 6.0%-15.0%) in the health care-based cohort. The molecular diagnostic yield ranged from 11.2% (95% CI, 6.4%-16.2%) for patients without intellectual disability, epilepsy, or autism spectrum disorder to 32.9% (95% CI, 25.7%-40.1%) for patients with all 3 comorbidities. Pathogenic and likely pathogenic variants were identified in 229 genes (29.5% of 1526 patients); 86 genes were mutated in 2 or more patients (20.1% of 1526 patients) and 10 genes with mutations were independently identified in both cohorts (2.9% of 1526 patients). Conclusions and Relevance: Among 2 cohorts of patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients. Further research is needed to understand the clinical implications of these findings.

Indexed as

Exome SequencingMutationAdolescentAdultCerebral PalsyChildChild, PreschoolCross-Sectional StudiesFemaleGenetic TestingGenetic VariationHumansMaleMiddle AgedNeurodevelopmental DisordersPrevalence

Identifiers

PMID33528536
PMCPMC7856544
OpenAlexW3127388865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.